BCAT2 can also be used to predict cancer cell responsiveness to ferroptosis-inducing therapies and be used as a sensitive biomarker to evaluate drug response in preclinical cancer models (Wang et al., 2021). The gene discussed is BCAT2; the disease is cancer.